

Supplementary Table 1. Comparisons of demographic data, clinical manifestations, and mortality of lupus nephritis patients

| | Death (n=5) | | Alive (n=70) | | Total (n=75) | | <i>p</i> value |
|-------------------------------------|-------------|----------|--------------|---------|--------------|---------|--------------------|
| Age | 37.8 | ±12.9 | 30.0 | ±11.5 | 30.5 | ±11.6 | 0.181 |
| Sex (Female) | 5 | (100.0%) | 64 | (91.4%) | 69 | (92.0%) | 1.000 ^f |
| Comorbidity | | | | | | | |
| Hypertension | 4 | (80.0%) | 38 | (54.3%) | 42 | (56.0%) | 0.377 ^f |
| DM | 0 | (0.0%) | 1 | (1.4%) | 1 | (1.3%) | 1.000 ^f |
| Lab data | | | | | | | |
| DUP (gm/day) | 2.8 | ±1.6 | 3.4 | ±2.6 | 3.3 | ±2.5 | 0.848 |
| Creatinine (mg/dl) | 1.6 | ±0.8 | 1.3 | ±1.1 | 1.3 | ±1.0 | 0.194 |
| eGFR (mL/min) | 48.1 | ±22.8 | 80.5 | ±54.8 | 78.3 | ±53.8 | 0.106 |
| Anti-dsDNA (WHO units/mL) | 115.9 | ±110.9 | 555.1 | ±393.4 | 525.8 | ±396.4 | 0.006** |
| C3 (mg/dl) | 61.6 | ±12.5 | 61.4 | ±25.3 | 61.4 | ±24.6 | 0.890 |
| C4 (mg/dl) | 16.8 | ±11.5 | 13.0 | ±8.5 | 13.3 | ±8.7 | 0.457 |
| SLEDAI | 10.2 | ±2.5 | 13.5 | ±4.3 | 13.3 | ±4.2 | 0.080 |
| Activity index | 4.6 | ±2.6 | 5.8 | ±4.4 | 5.7 | ±4.3 | 0.599 |
| cellular crescent | 2 | (40.0%) | 19 | (28.4%) | 21 | (29.2%) | 0.625 ^f |
| necrotizing lesion | 1 | (20.0%) | 37 | (55.2%) | 38 | (52.8%) | 0.182 ^f |
| endocapillary proliferation | 4 | (80.0%) | 53 | (79.1%) | 57 | (79.2%) | 1.000 ^f |
| wire loop | 2 | (40.0%) | 33 | (49.3%) | 35 | (48.6%) | 1.000 ^f |
| neutrophils, infiltration | 1 | (20.0%) | 23 | (34.3%) | 24 | (33.3%) | 0.659 ^f |
| interstitial inflammation | 3 | (60.0%) | 39 | (58.2%) | 42 | (58.3%) | 1.000 ^f |
| Chronicity index | 1.6 | ±1.1 | 2.1 | ±2.8 | 2.1 | ±2.7 | 0.875 |
| glomerular sclerosis | 3 | (60.0%) | 38 | (56.7%) | 41 | (56.9%) | 1.000 ^f |
| tubular, atrophy | 2 | (40.0%) | 27 | (40.3%) | 29 | (40.3%) | 1.000 ^f |
| interstitial fibrosis | 2 | (40.0%) | 28 | (41.8%) | 30 | (41.7%) | 1.000 ^f |
| fibrous crescent | 1 | (20.0%) | 4 | (6.0%) | 5 | (6.9%) | 0.310 ^f |
| Induction therapy | | | | | | | 0.658 |
| MPA | 1 | (20.0%) | 29 | (41.4%) | 30 | (40.0%) | |
| MPA combination | 1 | (20.0%) | 14 | (20.0%) | 15 | (20.0%) | |
| Cyclophosphamide | 2 | (40.0%) | 13 | (18.6%) | 15 | (20.0%) | |
| Azathioprine | 1 | (20.0%) | 14 | (20.0%) | 15 | (20.0%) | |
| Intravenous steroid pulse | 1 | (20.0%) | 3 | (4.3%) | 4 | (5.3%) | 0.246 ^f |
| Oral steroid starting dose (mg/day) | 27.5 | ±15.1 | 24.9 | ±10.9 | 25.0 | ±11.1 | 0.966 |

Chi-Square test. ^fFisher's Exact test. Mann-Whitney U test. **p*<0.05, ***p*<0.01.

DM: Diabetes mellitus; eGFR: estimated glomerular filtration rate; SLEDAI: SLE disease activity index; MPA: mycophenolic acid